Be Aware of Changes in the Erythropoiesis-Stimulating Agent REMS Program

You'll hear about changes in the REMS requirements for prescribing erythropoiesis-stimulating agents (ESA) in cancer patients.

For years, hospitals have been required to verify that prescribers ordering ESAs (Procrit, Epogen, Aranesp) are certified by the REMS program...AND that cancer patients sign an informed consent.

This is due to the fact that ESAs can speed up tumor growth...and death.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote